EP1663272A1 - Extrait de kava a teneur reduite en alcaloides - Google Patents

Extrait de kava a teneur reduite en alcaloides

Info

Publication number
EP1663272A1
EP1663272A1 EP04786236A EP04786236A EP1663272A1 EP 1663272 A1 EP1663272 A1 EP 1663272A1 EP 04786236 A EP04786236 A EP 04786236A EP 04786236 A EP04786236 A EP 04786236A EP 1663272 A1 EP1663272 A1 EP 1663272A1
Authority
EP
European Patent Office
Prior art keywords
extract
kava
organic
treatment
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04786236A
Other languages
German (de)
English (en)
Inventor
Wilhelm Berkulin
Björn FEISTEL
Frauke Gaedcke
Ivo Pischel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finzelberg GmbH and Co KG
Original Assignee
Finzelberg GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finzelberg GmbH and Co KG filed Critical Finzelberg GmbH and Co KG
Priority to EP04786236A priority Critical patent/EP1663272A1/fr
Publication of EP1663272A1 publication Critical patent/EP1663272A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava

Definitions

  • the present invention relates to a process for the production of a plant extract of kava (Piper methysticum), an extract obtainable according to the process according to the invention and the use of the extract.
  • Kava kava also known as intoxicant (Piper methysticum FORSTER, Piperaceae), is a close relative of black pepper and is native to Polynesia and Melanesia.
  • intoxicant Pier methysticum FORSTER, Piperaceae
  • the perennial shrub with 30 cm large, heart-shaped leaves grows to a height of approx. 3 m and forms a strong rhizome of up to 10 kg in 5 to 6 years.
  • the most important growers are Samoa and Fiji, where the propagation takes place exclusively via cuttings.
  • Kava-kava (also kawa-kawa) was distributed millennia ago by seafaring peoples on the Pacific Islands, for whom the roots of the psychoactive pepper variety were of great importance in cultural and religious life. The toning, refreshing drink was indispensable in daily use and at ceremonies all over Polynesia. It was also used in folk medicine.
  • lactones identified as ingredients have been clinically proven. They have a calming, antispasmodic, local anesthetic and muscle relaxant effect. However, they also show neurophysiological activity, which e.g. demonstrated in an improvement in sleep [Piscopo G; Alt Med Rev 1997; 2 (5): 355-364].
  • German and other western doctors have been successfully using kava-kava for years to treat anxiety and restlessness as a natural phyto-tranquilizer with few side effects.
  • the peeled, cut rhizome dried or fresh is used.
  • the roots were traditionally chewed for crushing. Extracts are now commercially available worldwide.
  • the main substances of kava-kava are approx. 15 compounds, chemical active substances known as cavaprone, with the largest proportions of kavain (5,6-dihydroxy-4-methoxy-6-styryl-2H-pyran-2-one) and make up its methoxy and dihydro derivatives Yangonin and Marindinin.
  • the process according to the invention for producing a plant extract of kava has the following steps:
  • organic extraction agents such as water-containing or anhydrous free alcohols, in particular alcohols, ketones, carboxylic esters, alkanes, chlorinated hydrocarbons and supercritical gases or mixtures thereof containing 1 to 3 carbon atoms, and also
  • the process according to the invention leads to a plant extract which is practically freed from alkaloid compounds.
  • the invention advantageously contains Extract of kava (Piper methysticum), obtainable according to the present invention, contains the majority of the naturally occurring kavapyrones in the kava plant.
  • leaves, stem bark or rhizome can be used as plant parts, fresh or dried.
  • the organic extractant is in particular methanol, ethanol, propanol, acetone, ethyl acetate or mixtures thereof with water, dichloromethane and / or supercritical carbon dioxide.
  • the treatment under basic or acidic conditions is carried out in particular using sodium hydroxide and lime liquor or using mineral acids such as sulfuric acid or hydrochloric acid. This treatment advantageously leads to the depletion of alkaloids.
  • Said treatment under basic or acidic conditions is preferably carried out under conditions in which the water content is more than 50% by volume, preferably more than 70% by volume, of the solution.
  • the pH should be 9 or more, preferably 10 or more. In one embodiment of the invention, the pH can also be 11 or more. Particularly suitable ranges are pH 9 to 11.
  • the pH should preferably be 3 or less, preferably 2.5 or less. In a preferred embodiment, it can also be 2 or less. Particularly suitable ranges are pH 3 to pH 1.5.
  • the treatment is typically carried out for a period of 5 minutes to 12 hours, more preferably between 0.5 and 6 hours, even more preferably between 1 and 4 hours.
  • the treatment can also be carried out at a somewhat elevated temperature.
  • Particularly suitable conditions for the treatment are temperatures between 0 and 80 ° C, more preferably between room temperature and 50 ° C.
  • Alkaloids and / or other substances can also be separated off by adsorption processes on adsorbents, for example on cation exchangers or organic polymer resins (for example Amberlite XAD). Liquid-liquid extraction is also an alternative or additional step.
  • the extract is extracted in aqueous solution with an organic solvent.
  • suitable solvents are butanol and ethyl acetate.
  • depletion steps can of course not only be carried out individually, but also in combination and in any order.
  • a suitable method is, for example, treatment with a cation exchanger in acid (H + ) form. This simultaneously lowers the pH and also enables adsorption on cation exchangers.
  • the invention also relates to a plant extract obtainable by the process according to the invention.
  • the extracts according to the invention contain the kavapyrones, which are mostly chemical derivatives of kavain (5,6-dihydroxy-4-methoxy-6-styryl-2H-pyran-2-one).
  • the effect of the method according to the invention may be based on the chemically relatively reduced stability of the alkaloids, which seem to be very susceptible to hydrolysis of the constituents to be structurally regarded as amide alkaloids.
  • This decomposition can be forced, for example, by basic or acidic saponification.
  • an amino and an acid component are released from the alkaloids, which should be less harmful or can be eliminated by suitable adsorbers, such as ion exchangers.
  • alkaloids With regard to the physical instability of the alkaloids, thermal lability was observed, especially in the presence of water, which is probably also manifested solvatolytically. Furthermore, the above-mentioned alkaloids, like their hydrolysis products, can have a basic or amphoteric character. Strong affinity for charged adsorbents was found. Such adsorbers are also very suitable hydrolysis catalysts and therefore preferred media for separating the alkaloid traces.
  • the extract according to the invention can be used for the production of medicaments, food supplements, veterinary products or cosmetics in liquid or solid extract preparations.
  • kava spissum extract obtained according to Example 1 100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. The mixture is then stirred at 55 ° C. Product temperature, so much sulfuric acid added dropwise until a pH of approx. 3 is reached. After a stirring time of 2 hours, the extract solution is cooled to room temperature and neutralized with an alkali solution. Precipitated precipitates are filtered off and the extract solution is evaporated down again to the spissumin extract.
  • the spissum contains 54% by weight Kavapyrone (HPLC) and 5 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • kava spissum extract obtained according to Example 1 100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. Then, with constant stirring at room temperature, as much lime is added dropwise until a pH of approx. 11 is reached. After stirring for 2 hours, the extract solution is neutralized with a mineral acid solution. Precipitated precipitates are separated and the extract solution is evaporated again to the spissum extract.
  • the spissum contains 49% by weight Kavapyrone (HPLC) and ⁇ 5 ppm alkaloid compounds calculated as pipermethystin (GC), each based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • kava spissum extract obtained according to Example 1 100 g of the kava spissum extract obtained according to Example 1 are redissolved in ethanol 80% v / v. Then, with constant stirring at 55 ° C product temperature, so much sulfuric acid is added dropwise until a pH of approx. 3 is established. After a stirring time of 2 hours, the extract solution is cooled to room temperature and neutralized with an alkali solution. Precipitated precipitates are separated and the extract solution is converted into an organic phase by stirring twice with the same volume of ethyl acetate. This is evaporated under reduced pressure.
  • the spissum obtained contains 62% by weight of Kavapyrone (HPLC) and ⁇ 5 ppm of alkaloid compounds calculated as pipermethystin (GC), in each case based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • kava spissum extract obtained according to Example 2 100 g of the kava spissum extract obtained according to Example 2 are suspended in sulfuric acid water at pH 1-2 with vigorous stirring at 40 ° C. for 1 h. The aqueous phase that separates is then removed. The extract is redissolved in ethanol 80% (V / V) and passed over a cation exchanger. The continuous aqueous-ethanolic eluates are then evaporated under reduced pressure.
  • the spissum obtained contains 47% by weight of Kavapyrone (HPLC) and ⁇ 5 ppm of alkaloid compounds calculated as pipermethystin (GC), in each case based on the dry extract.
  • HPLC Kavapyrone
  • GC pipermethystin
  • the extract is redissolved in 70% v / v ethanol and passed through a strongly acidic cation exchanger (sulfonic acid resin) in the form of a packed column.
  • the eluate obtained after passage through the column is evaporated in vacuo to spissum at 55 ° C.
  • This extract still contains a high proportion of 52% by weight of kavapyrones and is practically free of alkaloid compounds ( ⁇ 5 ppm), based in each case on the dry extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des procédés pour produire un extrait végétal de kava (Piper methysticum). Ces procédés consistent à extraire les matières végétales à l'aide d'agents d'extraction tels que des alcools libres hydratés ou anhydres, des cétones, des esters d'acide carboxylique, des alcanes, des hydrocarbures chlorés et des gaz ou des mélanges surcritiques, puis à traiter le résidu au moins partiellement libéré par les agents d'extraction dans des conditions acides (pH = 3) ou basiques (pH = 9) et/ou à mettre en oeuvre des processus d'adsorption sur des échangeurs de cations ou des adsorbants non chargés à base de résines polymères organiques.
EP04786236A 2003-08-27 2004-08-26 Extrait de kava a teneur reduite en alcaloides Withdrawn EP1663272A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04786236A EP1663272A1 (fr) 2003-08-27 2004-08-26 Extrait de kava a teneur reduite en alcaloides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03019343 2003-08-27
PCT/EP2004/051920 WO2005021017A1 (fr) 2003-08-27 2004-08-26 Extrait de kava a teneur reduite en alcaloides
EP04786236A EP1663272A1 (fr) 2003-08-27 2004-08-26 Extrait de kava a teneur reduite en alcaloides

Publications (1)

Publication Number Publication Date
EP1663272A1 true EP1663272A1 (fr) 2006-06-07

Family

ID=34259140

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04786236A Withdrawn EP1663272A1 (fr) 2003-08-27 2004-08-26 Extrait de kava a teneur reduite en alcaloides

Country Status (2)

Country Link
EP (1) EP1663272A1 (fr)
WO (1) WO2005021017A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102920790A (zh) * 2012-11-12 2013-02-13 沈阳药科大学 胡椒提取物在制备镇静催眠类药物或保健食品中的应用
CN118217328A (zh) * 2024-03-18 2024-06-21 西安绿天生物技术有限公司 一种具有敏感肌舒缓用途的高含量卡瓦提取物的制备方法及应用
CN117964831B (zh) * 2024-03-29 2024-08-16 广州伽能生物科技有限公司 一种醉椒素温敏分子印迹聚合物的制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5842686A (ja) * 1981-09-08 1983-03-12 T Hasegawa Co Ltd 天燃コシヨウ中の抗酸化成分の抽出法
DE4028945A1 (de) * 1990-09-12 1992-03-19 Schwabe Willmar Gmbh & Co Kawa-kawa-extrakt, verfahren zu seiner herstellung und seine verwendung
DE4401646A1 (de) * 1994-01-21 1995-07-27 Krewel Werke Gmbh Optimal freisetzende Kava-Extrakte
EP0987026A1 (fr) * 1998-08-21 2000-03-22 Max Zeller Söhne AG Procédé de préparation d'un extrait de Kawa-Kawa
GB2385289A (en) * 2002-01-18 2003-08-20 Advanced Phytonics Ltd Purifying a material using a non-aqueous solvent and an ion exchange resin or adsorbent.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005021017A1 *

Also Published As

Publication number Publication date
WO2005021017A1 (fr) 2005-03-10

Similar Documents

Publication Publication Date Title
DE3940092C2 (fr)
DE102014202318B4 (de) Verbessertes Verfahren zur Herstellung von Ginkgoextrakten
DE19756848C2 (de) Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen
EP0692257A1 (fr) Procédé de préparation de concentrés de produits actifs faibles en pesticides, à partir de plantes
DE69031481T2 (de) Verfahren zur Gewinnung von Ginkgoliden aus Ginkgoblättern und ihre Reinigung
EP0702957A1 (fr) Extraits d'herbe de la Saint-Jean
EP2493337B1 (fr) Procédé de production d'un extrait végétal riche en acide carnosique
EP1663272A1 (fr) Extrait de kava a teneur reduite en alcaloides
EP0382116B1 (fr) Procédé d'élimination des pesticides de la racine de ginseng
EP0874550B1 (fr) Extraction de substances contenues dans des constituants de neem
DE2656602C3 (de) Verfahren zum Extrahieren von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin aus Maulbeerpflanzen
DE3935772C2 (fr)
EP1391208A1 (fr) Procédé de préparation d'extraits de plantes à haute teneur en isoflavones
EP0508330B1 (fr) Procédé d'extraction du rhizoma petasitidis à l'aide de dioxyde de carbone
DE60108272T2 (de) Pharmazeutische zusammensetzung enthaltend (-)-secoisolariciresinol
DE4002938A1 (de) Verfahren zur herstellung von extrakten aus rhizoma petasitidis
AT392970B (de) Verfahren zur gewinnung eines ueberwiegend pentacyclische oxindolalkaloide enthaltenden alkaloidgemisches
DE102009040381A1 (de) Verfahren zur Isolierung von Alkaloiden aus Pflanzen
EP0665231A1 (fr) Procédé d'obtention d'alcoloides d'oxindole
DE10014670B4 (de) Verfahren zur Extraktion und Isolierung von Santonin aus Artemisia sp.
DE2609533A1 (de) Verfahren zur extraktion von wirkstoffen, insbesondere von heterosidestern, der kaffeesaeure, sowie diese verbindungen enthaltende arzneimittel
DE1617469C3 (de) Verfahren zur Gewinnung eines basischen Inhaltsstoffes aus Cabucala madagascariensis
DE1117593B (de) Verfahren zur Gewinnung von Alkaloidgemischen aus Rauwolfiapflanzen
DE3940095A1 (de) Extrakt aus blaettern von ginkgo biloba, verfahren zu seiner herstellung und den extrakt enthaltende arzneimittel
DE1617469B2 (de) Verfahren zur gewinnung eines basischen inhaltsstoffes aus cabucala madagascariensis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080709